Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)
Lamiae Grimaldi‐Bensouda(Conservatoire National des Arts et Métiers), Lucien Abenhaim(Serco (United Kingdom)), Yola Moride(Jewish General Hospital), Hélène Verdoux(Université de Bordeaux), Jacques Bénichou(National Cancer Institute), Guillaume Vaïva(Inserm), Bernard Astruc(Inserm), Frédéric Limosin(Inserm), Alban Fabre(Inserm), Béatrice Beaufils(Assistance Publique – Hôpitaux de Paris), Michel Rossignol(McGill University Health Centre), Florence Thibaut(Centre Hospitalier du Rouvray), Frédéric Rouillon(Centre Hospitalier Sainte-Anne), Bruno Falissard(Inserm)
Cited by 90
Related Papers
Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis: an open-label, non-inferiority, randomised controlled trial
|The Lancet|2011|674
Complicated grief after death of a relative in the intensive care unit
|European Respiratory Journal|2015|359
Sample size requirements for the internal validation of psychiatric scales
|International Journal of Methods in Psychiatric Research|2011|298